Cargando…

Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting

PURPOSE: The purpose of this study was to analyze the therapeutic strategies and estimate the health care resource consumption in patients with psoriatic arthritis (PsA). PATIENTS AND METHODS: An observational retrospective cohort analysis of administrative databases of six Italian Local Health Unit...

Descripción completa

Detalles Bibliográficos
Autores principales: Degli Esposti, L, Perrone, V, Sangiorgi, D, Alessandrini, D, Buda, S, Cantini, F, Mazzini, E, Toma, C, De Solda, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348972/
https://www.ncbi.nlm.nih.gov/pubmed/30774314
http://dx.doi.org/10.2147/PPA.S178603
_version_ 1783390203419820032
author Degli Esposti, L
Perrone, V
Sangiorgi, D
Alessandrini, D
Buda, S
Cantini, F
Mazzini, E
Toma, C
De Solda, F
author_facet Degli Esposti, L
Perrone, V
Sangiorgi, D
Alessandrini, D
Buda, S
Cantini, F
Mazzini, E
Toma, C
De Solda, F
author_sort Degli Esposti, L
collection PubMed
description PURPOSE: The purpose of this study was to analyze the therapeutic strategies and estimate the health care resource consumption in patients with psoriatic arthritis (PsA). PATIENTS AND METHODS: An observational retrospective cohort analysis of administrative databases of six Italian Local Health Units was performed. Patients ≥18 years with a hospitalization discharge diagnosis of PsA (International Classification of Diseases, Ninth Revision code: 696.0) or exemption code (045.696.0) for PsA from January 1, 2010 to December 31, 2015 (inclusion period), with at least one prescription of any therapy used for PsA were included. The index date (ID) was the first date matching with at least one of the inclusion criteria during the inclusion period. All patients were followed up after the ID until the end of data availability. Baseline C-reactive protein (CRP) levels (±6 months in relation to the ID) were also analyzed. RESULTS: A total of 2,408 (prevalence 0.83 per 1,000) patients with PsA (male 52%; median age 54 years) were included in the study; patients were already treated for PsA in 42.4% of cases. At 1 year of follow-up, 73% of the patients received one systemic drug, while 22% of patients received two systemic drugs; in addition, our results show an increase in the number of add-on or switches in a longer follow-up period. The utilization of biologic agents was higher among patients with previous PsA treatment, showing a progression of the pathology. Overall, a medium/high level of CRP at baseline was observed among more than half of the overall sample, with slight changes across subgroups in analysis. The average health care costs were €1,966.4 and €13,914 per year for patients treated with conventional systemic therapy and biological agents, respectively. CONCLUSION: A better knowledge of prescription therapeutic scheme and economic burden of PsA could stimulate the rational development of health programs aimed at potentiating services for its management.
format Online
Article
Text
id pubmed-6348972
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63489722019-02-15 Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting Degli Esposti, L Perrone, V Sangiorgi, D Alessandrini, D Buda, S Cantini, F Mazzini, E Toma, C De Solda, F Patient Prefer Adherence Original Research PURPOSE: The purpose of this study was to analyze the therapeutic strategies and estimate the health care resource consumption in patients with psoriatic arthritis (PsA). PATIENTS AND METHODS: An observational retrospective cohort analysis of administrative databases of six Italian Local Health Units was performed. Patients ≥18 years with a hospitalization discharge diagnosis of PsA (International Classification of Diseases, Ninth Revision code: 696.0) or exemption code (045.696.0) for PsA from January 1, 2010 to December 31, 2015 (inclusion period), with at least one prescription of any therapy used for PsA were included. The index date (ID) was the first date matching with at least one of the inclusion criteria during the inclusion period. All patients were followed up after the ID until the end of data availability. Baseline C-reactive protein (CRP) levels (±6 months in relation to the ID) were also analyzed. RESULTS: A total of 2,408 (prevalence 0.83 per 1,000) patients with PsA (male 52%; median age 54 years) were included in the study; patients were already treated for PsA in 42.4% of cases. At 1 year of follow-up, 73% of the patients received one systemic drug, while 22% of patients received two systemic drugs; in addition, our results show an increase in the number of add-on or switches in a longer follow-up period. The utilization of biologic agents was higher among patients with previous PsA treatment, showing a progression of the pathology. Overall, a medium/high level of CRP at baseline was observed among more than half of the overall sample, with slight changes across subgroups in analysis. The average health care costs were €1,966.4 and €13,914 per year for patients treated with conventional systemic therapy and biological agents, respectively. CONCLUSION: A better knowledge of prescription therapeutic scheme and economic burden of PsA could stimulate the rational development of health programs aimed at potentiating services for its management. Dove Medical Press 2019-01-22 /pmc/articles/PMC6348972/ /pubmed/30774314 http://dx.doi.org/10.2147/PPA.S178603 Text en © 2019 Degli Esposti et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Degli Esposti, L
Perrone, V
Sangiorgi, D
Alessandrini, D
Buda, S
Cantini, F
Mazzini, E
Toma, C
De Solda, F
Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting
title Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting
title_full Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting
title_fullStr Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting
title_full_unstemmed Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting
title_short Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting
title_sort therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an italian setting
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348972/
https://www.ncbi.nlm.nih.gov/pubmed/30774314
http://dx.doi.org/10.2147/PPA.S178603
work_keys_str_mv AT degliespostil therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting
AT perronev therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting
AT sangiorgid therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting
AT alessandrinid therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting
AT budas therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting
AT cantinif therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting
AT mazzinie therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting
AT tomac therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting
AT desoldaf therapeuticstrategiesutilizationandresourceconsumptioninpatientstreatedforpsoriaticarthritisfindingsfromarealworldanalysisinanitaliansetting